The historical rank and industry rank for Theralase Technologies's FCF Margin % or its related term are showing as below:
TSXV:TLT'
s FCF Margin % Range Over the Past 10 Years
Min: -736.41 Med: -396.41 Max: -77.85
Current: -368.22
During the past 13 years, the highest FCF Margin % of Theralase Technologies was -77.85%. The lowest was -736.41%. And the median was -396.41%.
TSXV:TLT's FCF Margin % is ranked worse than 91.17% of 815
companies
in the Medical Devices & Instruments industry
Industry Median: -0.1
vs TSXV:TLT: -368.22
Theralase Technologies FCF Margin % Related Terms
Theralase Technologies FCF Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSXV:TLT vs ABT, SYK, MDT: FCF Margin % Comparison
For the Medical Devices subindustry, Theralase Technologies's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Theralase Technologies FCF Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Theralase Technologies's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Theralase Technologies's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Theralase Technologies (TSXV:TLT) has a FCF Margin % of -184.96% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Theralase Technologies and its competitors. According to the industry distribution chart, Theralase Technologies ranks #743 out of 815 companies in the Medical Devices & Instruments industry, placing it in the top 91.2%.
Is Theralase Technologies' FCF Margin % too high?
Theralase Technologies' current FCF Margin % is -184.96%. Based on the distribution chart, Theralase Technologies ranks #743 out of 815 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Theralase Technologies has a GF Score™ of 39/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Theralase Technologies' FCF Margin % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Theralase Technologies ranks #743 out of 815 companies for FCF Margin %. This places Theralase Technologies in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Medical Devices & Instruments company?
A good FCF Margin % depends on the Medical Devices & Instruments industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Theralase Technologies and its competitors. Theralase Technologies's current FCF Margin % is -184.96%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Theralase Technologies stock overvalued right now?
Based on GuruFocus' analysis, Theralase Technologies (TSXV:TLT) is currently considered Modestly Overvalued. The stock's GF Value™ is C$0.18, compared to a current price of C$0.23 — trading 27.8% above its estimated fair value. The current FCF Margin % is -184.96%. Theralase Technologies' overall GF Score™ is 39/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Theralase Technologies (TSXV:TLT), the current FCF Margin % is -184.96% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Theralase Technologies (TSXV:TLT) Overvalued in 2026?
Based on GuruFocus' analysis, Theralase Technologies stock appears to be overvalued.
The current stock price of C$0.23 is trading 27.8% above its estimated GF Value™ of C$0.18.
GuruFocus considers Theralase Technologies to be Modestly Overvalued.
Key valuation signals for TSXV:TLT:
FCF Margin %: -184.96%
GF Value™: C$0.18 vs. price of C$0.23 (27.8% above fair value)
No single metric tells the full story. See the TSXV:TLT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Theralase Technologies Inc brings CLT to patients and personalized ACT to patients based on individual tissue characteristics. It is two separate reportable operating divisions; the Drug Division and the Device Division. The Drug Division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs), and activates them with proprietary and patent-pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The Device Division designs develops, manufactures, and markets proprietary super-pulsed laser technology indicated and cleared by Health Canada and the Food and Drug Administration (FDA) for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions.
39GF Score
Get the complete analysis for TSXV:TLT
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSXV:TLT has been successfully added to your 
